dc.contributor.author | Bär, Christian | |
dc.contributor.author | Povedano, Juan Manuel | |
dc.contributor.author | Serrano, Rosa | |
dc.contributor.author | Benitez-Buelga, Carlos | |
dc.contributor.author | Popkes, Miriam | |
dc.contributor.author | Formentini, Ivan | |
dc.contributor.author | Bobadilla, Maria | |
dc.contributor.author | Bosch, Fatima | |
dc.contributor.author | Blasco, MA | |
dc.date.accessioned | 2024-04-04T09:35:24Z | |
dc.date.available | 2024-04-04T09:35:24Z | |
dc.date.issued | 2016-04-07 | |
dc.identifier.citation | Blood . 2016 ;127(14):1770-9 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/19113 | |
dc.description | This study was funded by the Spanish Ministry of Economy and Competitiveness, the Fundacion Botin, and the Roche Extending the Innovation Network Academia Partnering Program (M.A.B.). | es_ES |
dc.description.abstract | Aplastic anemia is a fatal bone marrow disorder characterized by peripheral pancytopenia and marrow hypoplasia. The disease can be hereditary or acquired and develops at any stage of life. A subgroup of the inherited form is caused by replicative impairment of hematopoietic stem and progenitor cells due to very short telomeres as a result of mutations in telomerase and other telomere components. Abnormal telomere shortening is also described in cases of acquired aplastic anemia, most likely secondary to increased turnover of bone marrow stem and progenitor cells. Here, we test the therapeutic efficacy of telomerase activation by using adeno-associated virus (AAV)9 gene therapy vectors carrying the telomerase Tert gene in 2 independent mouse models of aplastic anemia due to short telomeres (Trf1- and Tert-deficient mice). We find that a high dose of AAV9-Tert targets the bone marrow compartment, including hematopoietic stem cells. AAV9-Tert treatment after telomere attrition in bone marrow cells rescues aplastic anemia and mouse survival compared with mice treated with the empty vector. Improved survival is associated with a significant increase in telomere length in peripheral blood and bone marrow cells, as well as improved blood counts. These findings indicate that telomerase gene therapy represents a novel therapeutic strategy to treat aplastic anemia provoked or associated with short telomeres. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject.mesh | Dependovirus | es_ES |
dc.subject.mesh | Telomere Homeostasis | es_ES |
dc.subject.mesh | Transduction, Genetic | es_ES |
dc.subject.mesh | Anemia, Aplastic | es_ES |
dc.subject.mesh | Animals | es_ES |
dc.subject.mesh | Disease Models, Animal | es_ES |
dc.subject.mesh | Genetic Therapy | es_ES |
dc.subject.mesh | Hematopoietic Stem Cells | es_ES |
dc.subject.mesh | Mice | es_ES |
dc.subject.mesh | Mice, Knockout | es_ES |
dc.subject.mesh | Telomerase | es_ES |
dc.subject.mesh | Telomere | es_ES |
dc.title | Telomerase gene therapy rescues telomere length, bone marrow aplasia, and survival in mice with aplastic anemia. | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.identifier.pubmedID | 26903545 | es_ES |
dc.format.volume | 127 | es_ES |
dc.format.number | 14 | es_ES |
dc.format.page | 1770 | es_ES |
dc.identifier.doi | 10.1182/blood-2015-08-667485 | es_ES |
dc.contributor.funder | Ministerio de Economía e Innovación (España) | es_ES |
dc.contributor.funder | Fundacion Botin | es_ES |
dc.contributor.funder | Roche | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1528-0020 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1182/blood-2015-08-667485. | es_ES |
dc.identifier.journal | Blood | es_ES |
dc.repisalud.institucion | CNIO | es_ES |
dc.repisalud.orgCNIO | CNIO::Grupos de investigación::Grupo de Telómeros y Telomerasa | es_ES |
dc.rights.accessRights | open access | es_ES |